BridgeMD
Compares treatment options for COPD Exacerbation
Official title DUET Versus Standard Interface for Hypercapnic COPD Patients
ClinicalTrials.gov ID: NCT05829083
What this study is testing
- What it's testing
- The goal of this clinical trial is to compare the new asymmetric nasal high flow interface with the conventional high flow nasal cannula in patients with COPD exacerbation. The main questions the study aims to answer are: Does the use of the asymmetric interface lead to: 1.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- acute exacerbation of COPD (defined as any worsening of the patient's respiratory symptoms that is beyond normal day-to-day variations and leads to...
- mild-to-moderate acute hypercapnic respiratory failure (defined as 7.35\>pH\>7.25 and arterial CO2 tension (PaCO2) \>45 mmHg)
You likely can't join if
- acute on chronic hypercapnic respiratory failure
- severe facial deformity, facial burns, fixed upper airway obstruction
- indication for imminent intubation and invasive mechanical ventilation (i.e. respiratory or cardiac arrest, diminished consciousness (Glasgow coma...
- psychomotor agitation inadequately controlled by sedation
- massive aspiration
- persistent inability to remove respiratory secretions
See the full eligibility criteria
- acute exacerbation of COPD (defined as any worsening of the patient's respiratory symptoms that is beyond normal day-to-day variations and leads to change in medication)
- mild-to-moderate acute hypercapnic respiratory failure (defined as 7.35\>pH\>7.25 and arterial CO2 tension (PaCO2) \>45 mmHg)
- acute on chronic hypercapnic respiratory failure
- severe facial deformity, facial burns, fixed upper airway obstruction
- indication for imminent intubation and invasive mechanical ventilation (i.e. respiratory or cardiac arrest, diminished consciousness (Glasgow coma score \<8)
- psychomotor agitation inadequately controlled by sedation
- massive aspiration
- persistent inability to remove respiratory secretions
- severe haemodynamic instability unresponsive to fluids and vasoactive drugs
- severe ventricular or supraventricular arrhythmias
- life threatening hypoxaemia
The study team makes the final eligibility decision.
Where it's taking place
- Athens, Greece
- Larissa, Greece
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Athens, Greece; Larissa, Greece. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.